Nurix Therapeutics presents positive preclinical data on pipeline programs at ACR Convergence 2024

From GlobeNewswire: 2024-11-17 10:30:00

Nurix Therapeutics presented preclinical data on two pipeline programs, NX-5948 and GS-6791, at ACR Convergence 2024. NX-5948 is a BTK degrader being developed for inflammation and autoimmune diseases, while GS-6791 targets IRAK4 for rheumatoid arthritis. Data showed NX-5948’s efficacy in multiple inflammatory disease models and GS-6791’s potent inhibition of inflammatory signaling and efficacy in arthritis models. Nurix’s drug discovery platform focuses on E3 ligases to modulate protein levels for cancer and inflammatory conditions. Nurix is advancing targeted protein degraders and inhibitors for clinical development, with GS-6791 being developed in partnership with Gilead Sciences.



Read more at GlobeNewswire: Nurix Therapeutics Presents Preclinical Data from Two